Clinical trials of immunosuppression in lung transplantation: A coming of age

Transplantation

Volumn 81, Issue 7, 2006, Pages 980-981

  Fisher, Andrew J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; BRONCHIOLITIS OBLITERANS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LUNG TRANSPLANTATION; MULTICENTER STUDY; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

CLINICAL TRIALS; HUMANS; IMMUNOSUPPRESSION; LUNG TRANSPLANTATION;

EID: 33646356240     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000202721.90146.97     Document Type: Note

References (4)

1. Knoop C, Haverich A, Fischer S. Immunosuppressive therapy after human lung transplantation. Eur Respir J 2004; 23: 159-171.
2. Trulock Ep, Edwards LB, Taylor DO, et al. Registry of the International Society of Heart and Lung Transplantation: Twenty-second official adult lung and heart-lung report 2005. J Heart Lung Transplant 2005; 24 (8): 956-967.
3. McNeil K, Glanville AR, Wahlers T, et al. Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients. Transplantation 2006; 81: 998-1003.
4. Palmer SA, Baz MA, Sanders L, et al. Results of a randomised prospective multicentre trial of mycophenolate mofetil versus Azathioprine in the prevention of acute lung allograft rejection. Transplantation 2001; 71: 1772-1776.